Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. The cancer molecule will be developed for treating patients with HER2+ cancer, including gastric, pancreatic and breast cancer.

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

Pharmaceutical Technology

MAY 4, 2023

The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results. This cohort showed a safety profile identical to that found in older children and adults.

In-Vitro 246

In-Vitro Genetic Disease Medicine Genetics 246

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

JANUARY 4, 2023

A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

NOVEMBER 9, 2022

ProPhase Labs’ wholly owned subsidiary ProPhase BioPharma has entered a two-year collaboration agreement with Dana-Farber Cancer Institute for further research and development of Linebacker-1 (LB-1). LB-1 will be given along with chemotherapy agents in-vitro, in various cell lines, and in-vivo subcutaneous mouse tumour models in the project.

In-Vivo 130

In-Vivo Development In-Vitro Scientist 130

Pharmaceutical Technology

APRIL 27, 2023

The treatment is now indicated for CF patients with a minimum of one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or with a mutation in the CFTR gene that responds to Trikafta based on in vitro data. It was previously approved to treat CF in children aged between six and 11 years.

FDA Approval 246

FDA Approval In-Vitro Drugs Gene 246

Pharmaceutical Technology

NOVEMBER 10, 2022

NRG Therapeutics has raised Series A funds worth $18.3m (£16m) to progress the development of mitochondrial therapeutics to treat neurodegenerative ailments such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). This could possibly stop or substantially slow down disease progression in Parkinson’s or ALS patients.

Development 130

Development In-Vitro Clinical Development Medicine 130

XTalks

NOVEMBER 25, 2024

XTALKS WEBINAR: Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data Live and On-Demand: Thursday, January 16, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

In-Vivo 105

In-Vivo FDA Approval In-Vitro Drugs 105

Pharmaceutical Technology

JANUARY 6, 2023

The preparation of a semi-solid dosage form – from formulation and development, to scale-up, commercial manufacturing, and packaging – should ideally take place under one roof in a contiguous, end-to-end workflow to avoid unnecessary equipment and process changes. Optimising development and scale-up. Particle distribution. Grittiness.

Production 130

Production Manufacturing Development Bioequivalency 130

BioPharma Reporter

JANUARY 28, 2021

In vitro studies found the Pfizer/BioNTech COVID-19 vaccine elicits antibodies against both the UK and South African virus strains.

In-Vitro 119

In-Vitro Vaccination Vaccine Antibody 119

Pharma Mirror

AUGUST 30, 2022

The testing facility, located in North Carolina, provides supportive technology at no cost allowing companies to test and prove their cell-based products at various stages of development. By eliminating the fluctuations and suboptimal transients caused by.

Medicine 130

Medicine In-Vitro Production Manufacturing 130

pharmaphorum

MARCH 4, 2021

UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. A scheme providing £500 payments to people self-isolating has been extended in England until the summer.

Vaccination 105

Vaccination Vaccine Development Life Science 105

BioTech 365

MARCH 29, 2021

Insights on the In-vitro Diagnostics Global Market to 2027 – Development of Condition-Specific Markers and Tests Presents Opportunities – ResearchAndMarkets.com Insights on the In-vitro Diagnostics Global Market to 2027 – Development of Condition-Specific Markers and Tests Presents Opportunities – ResearchAndMarkets.com … (..)

In-Vitro 40

In-Vitro Marketing Development 40

Pharma Mirror

FEBRUARY 18, 2021

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc. Capable of delivering any FDA approved.

Drug Delivery 130

Drug Delivery In-Vivo In-Vitro Drugs 130

XTalks

MARCH 1, 2021

The study is part of a broad development plan to assess the durability of the immunogenic responses elicited by its vaccine and the emergence of new SARS-CoV-2 variants. The study will be a part of current Phase I, II and III trials. The third booster will be given to participants from the Phase I study in the US.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

Medical Xpress

JANUARY 23, 2023

Researchers have developed a new tool and technique that uses "vortex ultrasound"—a sort of ultrasonic tornado—to break down blood clots in the brain. The new approach worked more quickly than existing techniques to eliminate clots formed in an in vitro model of cerebral venous sinus thrombosis (CVST).

In-Vitro 98

In-Vitro Development Research Cardiology 98

pharmaphorum

SEPTEMBER 29, 2022

Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to U.S. If so, developers must develop and execute on a regulatory strategy. The FDA’s General Approach to Regulating mHealth Products.

Development 104

Development Regulation Production Life Science 104

Pharmaceutical Technology

APRIL 25, 2023

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

Scienmag

OCTOBER 24, 2021

Therefore, understanding the local invasion mechanism is warranted in developing more effective therapeutic approaches, and identifying markers that predict poor prognosis. Many diagnosed patients relapse, despite radical resection of the primary oral squamous cell carcinoma (OSCC) lesion.

In-Vitro 67

In-Vitro In-Vivo Development 67

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? This involves the use of an individualized computer simulation for medical device or drug development. Want to learn more?

Trials 98

Trials In-Vivo In-Vitro Clinical Trials 98

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Scienmag

AUGUST 31, 2020

The project seeks to kickstart the development of an open access “Organoid Cell Atlas” By creating well-characterized in vitro […].

In-Vitro 98

In-Vitro Research Development Bioinformatics 98

Pharmaceutical Technology

MAY 12, 2023

Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas announced the news in a May 10 statement.

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

Pharmaceutical Technology

APRIL 12, 2023

FoundationOne CDx is a sequencing-based in vitro diagnostic device that can identify alterations in 324 genes from tumour samples. Repotrectinib has been developed to combat cancer resistance to existing therapies and exert consistent anti-tumor activity. The ROS1 gene is altered in approximately in 1-2% of lung cancer patients.

Genome 130

Genome Genomics In-Vitro Gene 130

Pharmaceutical Technology

MAY 31, 2023

ZNA-1041 is under clinical development by F. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases.

In-Vitro 130

In-Vitro Clinical Trials Clinical Trials Drugs 130

pharmaphorum

OCTOBER 4, 2022

Such non-device CDS are: (1) not intended to acquire, process, or analyse a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system (Criterion 1); (2) intended for the purpose of displaying, analysing, or printing medical information about a patient or other medical information (e.g.

Development 105

Development Regulation Cosmetics Life Science 105

XTalks

JANUARY 21, 2025

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

OCTOBER 16, 2020

This week’s round up features a digital solution for adapting clinical trials to ease the burden on the clinical research industry and an in vitro model that mimics the human airway epithelium using a newly developed technology platform. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials Trials 52

Medical Xpress

APRIL 6, 2023

Fertility and in vitro fertilization (IVF) centers are receiving increasing numbers of infected patients. Since December 2022, the nationwide control policy on the COVID-19 epidemic has been changed in China. However, there is still a lack of high-quality evidence on the effects of the virus on human oocytes and early-stage embryos.

In-Vitro 74

In-Vitro Development 74

Pharmaceutical Technology

NOVEMBER 4, 2022

The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. at closing.

In-Vivo 130

In-Vivo In-Vitro Genetics Drugs 130

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

BioTech 365

OCTOBER 8, 2020

DUBLIN–(BUSINESS WIRE)–The “2020 Three Scenarios of the Future In Vitro Diagnostics Market: Business-as-Usual, Economic Austerity, Technological Breakthroughs” report has been added to ResearchAndMarkets.com’s offering. … Continue reading →

In-Vitro 40

In-Vitro Marketing Development 40

Pharmaceutical Technology

MAY 10, 2023

Under the two-year deal, both parties expect to develop new treatment methods for patients’ unmet AML and breast cancer needs at a reasonable price. The research teams will examine the use of CytoMed’s allogeneic gdTc on multiple AML and breast cancer subtypes in vitro and in vivo.

Gene Therapy 147

Gene Therapy In-Vivo In-Vitro Gene 147

Pharmaceutical Technology

FEBRUARY 1, 2023

The dual FLT-3 and Aurora kinase inhibitor EP0042 is being developed to treat AML patients who have developed FLT3 inhibitor resistance. Ellipses Pharma stated that the dual FLT3 inhibition and Aurora kinase demonstrated to overcome the acquired resistance to selectively inhibit FLT3 in vitro and in vivo.

FDA Approval 130

FDA Approval In-Vivo In-Vitro Trials 130

Worldwide Clinical Trials

JUNE 21, 2024

Currently, there are 12 approved ADC drugs, and several hundred more are in the development pipeline. Four distinct challenges were discussed at ASCO involving ADC development, including: Target Expression Levels : The targeted antigen must be sufficiently expressed on tumor cells.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Pharmaceutical Technology

MAY 16, 2023

Nuvectis Pharma chairman and CEO Ron Bentsur stated: “The IND clearance by the FDA is a significant milestone for the NXP900 development programme and for our overall corporate strategy, further demonstrating our ability to execute our business plan. The approval also includes clearance for a Phase I clinical trial protocol of NXP900.

In-Vivo 130

In-Vivo In-Vitro Clinical Trials Clinical Trials 130

BioPharma Reporter

DECEMBER 6, 2021

Trince, a spin-off of Ghent University (UGent) that is focused on advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo, has raised â4m from investors.

In-Vivo 87

In-Vivo In-Vitro Development 87